SELLAS Life Sciences (SLS) Liabilities and Shareholders Equity (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $26.5 million as the latest value for Q3 2024.
- On a quarterly basis, Liabilities and Shareholders Equity changed N/A to $26.5 million in Q3 2024 year-over-year; TTM through Dec 2024 was $41.6 million, a 67.94% increase, with the full-year FY2023 number at $6.2 million, down 70.31% from a year prior.
- Liabilities and Shareholders Equity was $26.5 million for Q3 2024 at SELLAS Life Sciences, up from $15.1 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $46.0 million in Q4 2020 to a low of $6.2 million in Q4 2023.
- A 5-year average of $26.8 million and a median of $26.0 million in 2022 define the central range for Liabilities and Shareholders Equity.
- Peak YoY movement for Liabilities and Shareholders Equity: soared 177.25% in 2020, then crashed 70.31% in 2023.
- SELLAS Life Sciences' Liabilities and Shareholders Equity stood at $46.0 million in 2020, then crashed by 42.94% to $26.3 million in 2021, then fell by 20.29% to $20.9 million in 2022, then plummeted by 70.31% to $6.2 million in 2023, then soared by 326.19% to $26.5 million in 2024.
- Per Business Quant, the three most recent readings for SLS's Liabilities and Shareholders Equity are $26.5 million (Q3 2024), $15.1 million (Q2 2024), and $6.2 million (Q4 2023).